Neutra Past Earnings Performance
Past criteria checks 0/6
Neutra has been growing earnings at an average annual rate of 32.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 36.8% per year.
Key information
32.7%
Earnings growth rate
100.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 36.8% |
| Return on equity | n/a |
| Net Margin | -269.2% |
| Last Earnings Update | 30 Apr 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Neutra makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 24 | 0 | 0 | 0 | 0 |
| 31 Jan 24 | 0 | 0 | 0 | 0 |
| 31 Oct 23 | 0 | 0 | 0 | 0 |
| 31 Jul 23 | 0 | -1 | 0 | 0 |
| 30 Apr 23 | 0 | -1 | 0 | 0 |
| 31 Jan 23 | 0 | -1 | 0 | 0 |
| 31 Oct 22 | 0 | 0 | 0 | 0 |
| 31 Jul 22 | 0 | -1 | 0 | 0 |
| 30 Apr 22 | 0 | -1 | 1 | 0 |
| 31 Jan 22 | 0 | -1 | 1 | 0 |
| 31 Oct 21 | 0 | -1 | 1 | 0 |
| 31 Jul 21 | 0 | -1 | 0 | 0 |
| 30 Apr 21 | 0 | -1 | 0 | 0 |
| 31 Jan 21 | 0 | -1 | 0 | 0 |
| 31 Oct 20 | 0 | -1 | 0 | 0 |
| 31 Jul 20 | 0 | -1 | 0 | 0 |
| 30 Apr 20 | 0 | -1 | 0 | 0 |
| 31 Jan 20 | 0 | -1 | 0 | 0 |
| 31 Oct 19 | 0 | -1 | 0 | 0 |
| 31 Jul 19 | 0 | -2 | 2 | 0 |
| 30 Apr 19 | 0 | -2 | 2 | 0 |
| 31 Jan 19 | 0 | -2 | 2 | 0 |
| 31 Oct 18 | 0 | -2 | 2 | 0 |
| 31 Jul 18 | 0 | 0 | 0 | 0 |
| 30 Apr 18 | 0 | 0 | 0 | 0 |
| 31 Jan 18 | 0 | -1 | 0 | 0 |
| 31 Oct 17 | 0 | -1 | 0 | 0 |
| 31 Jul 17 | 0 | -1 | 0 | 0 |
| 30 Apr 17 | 0 | -1 | 0 | 0 |
| 31 Jan 17 | 0 | -1 | 0 | 0 |
| 31 Oct 16 | 0 | -1 | 1 | 0 |
| 31 Jul 16 | 0 | -1 | 1 | 0 |
| 30 Apr 16 | 0 | -1 | 1 | 0 |
| 31 Jan 16 | 0 | -1 | 1 | 0 |
| 31 Oct 15 | 0 | -1 | 1 | 0 |
| 31 Jul 15 | 0 | -2 | 1 | 0 |
| 30 Apr 15 | 0 | -2 | 1 | 0 |
| 31 Jan 15 | 0 | -2 | 1 | 0 |
| 31 Oct 14 | 0 | -2 | 1 | 0 |
| 31 Jul 14 | 0 | -2 | 1 | 0 |
| 30 Apr 14 | 0 | -1 | 1 | 0 |
Quality Earnings: NTRR is currently unprofitable.
Growing Profit Margin: NTRR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NTRR is unprofitable, but has reduced losses over the past 5 years at a rate of 32.7% per year.
Accelerating Growth: Unable to compare NTRR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTRR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: NTRR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.